Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
MOUNTAIN VIEW, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors (“MACs”) retired their local coverage determinations (“LCDs”) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate for continued patient access to clinically proven safe and effective glaucoma treatments. The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.
Related news for (IRIX)
- Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
- Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
- Iridex Announces Strategic Investment in the Company
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
- Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
